<DOC>
	<DOCNO>NCT02065466</DOCNO>
	<brief_summary>1.1 . Primary Objectives 1 . To determine nab-paclitaxel temozolomide combine full dose bevacizumab therapy patient newly diagnose brain metastasis metastatic malignant melanoma . - To define MTD combination ( Phase I component ) . - To determine progression free survival ( Phase II component ) . 1.2 . Secondary Objectives 1 . To separately evaluate response rate duration brain extra-cranial systemic metastasis . 2 . To define toxicity regimen . 3 . To tabulate toxicity radiotherapy brain compare know toxicity radiotherapy brain melanoma brain metastasis . 4 . To use data generate plan definitive control clinical trial combination . 5 . To determine overall response rate ( Phase II component ) .</brief_summary>
	<brief_title>Combo Abraxane , TMZ , Bevacizumab Metastatic Melanoma With Brain Metastases</brief_title>
	<detailed_description />
	<mesh_term>Melanoma</mesh_term>
	<mesh_term>Neoplasm Metastasis</mesh_term>
	<mesh_term>Brain Neoplasms</mesh_term>
	<mesh_term>Paclitaxel</mesh_term>
	<mesh_term>Temozolomide</mesh_term>
	<mesh_term>Albumin-Bound Paclitaxel</mesh_term>
	<mesh_term>Bevacizumab</mesh_term>
	<mesh_term>Dacarbazine</mesh_term>
	<criteria>Histologically cytologically confirm malignant melanoma clinical evidence metastatic disease brain . Mucosal ocular melanoma include . Newly develop inoperable brain metastasis without associate hemorrhage midline shift . Inoperable metastatic extra cranial stage III IV disease . Diagnostic quality MRI brain contraindicate contrast CT scan head perform within 28 day prior registration . Measurable metastasis brain , define least one lesion accurately measure least one dimension ( long diameter record ) &gt; 10 mm brain MRI/CT scan . CT scan chest , abdomen pelvis PET CT scan perform within 28 day study registration . For disease outside brain , tumor must &gt; 10 mm CT scan . Prior therapy allow prior therapy nabpaclitaxel , paclitaxel , temozolomide , DTIC bevacizumab . Bevacizumab may initiate 4 week surgical resection radiation therapy completion . Age 18 old . Preexisting peripheral neuropathy must &lt; Grade 2 ( per CTCAE 4.0 ) time registration . Negative serum urine βhCG pregnancy test screening patient childbearing potential . Women childbearing potential sexually active male must use effective contraception method treatment three month complete treatment . ECOG Performance status 01 . Estimated life expectancy great 2 month . Patients must adequate organ function define ( must evaluate within 14 day prior registration ) : leukocytes &gt; 3,000/mcL absolute neutrophil count &gt; 1,500/mcL platelet &gt; 100,000/mcL Hemoglobin &gt; 9.0 g/dL AST ( SGOT ) /ALT ( SGPT ) &lt; 2.5 X institutional upper limit Alkaline phosphatase &lt; 2.5 X institutional upper limit Total bilirubin &lt; 1.5 X institutional upper limit normal ( unless associate Gilbert 's syndrome ) serum creatinine &lt; 1.5 mg/dL OR 1.5 x institutional normal LDH restriction INR &lt; 1.5 PTT WNL Urine protein ( UPC ) ratio 1.0 OR Urine dipstick proteinuria . Urine dipstick proteinuria ≥ 2+ ( patient discover ≥2+ proteinuria dipstick urinalysis baseline undergo 24 hour urine collection must demonstrate ≤ 1g protein 24 hour eligible ) . Able render inform consent . Prior surgical resection brain metastasis . History allergic reaction attribute compound similar chemical biologic composition bevacizumab , nabpaclitaxel temozolomide . Uncontrolled intercurrent illness include , limited , ongoing active infection require parenteral antibiotic , symptomatic congestive heart failure , unstable angina pectoris , untreated cardiac arrhythmia peripheral vascular disease . History myocardial infarction unstable angina within 6 month prior Day 1 . History stroke transient ischemic attack within 6 month prior Day 1 . History abdominal fistula , gastrointestinal perforation , intraabdominal abscess within 6 month prior study screen . Serious , nonhealed wound , ulcer , bone fracture . History hepatitis B , C HIV . Uncontrolled hypertension chronic renal disease . No known bleeding diathesis . Known hypersensitivity human albumin . Surgery within 4 week study registration . Must fully recover fully heal prior surgery . Patients chemotherapy extra cranial radiotherapy within 4 week prior study screen recover adverse event due agent administer 4 week prior completion study screen . Evidence concurrent active malignancy . Pregnant nursing . Not receive investigational agent .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>April 2016</verification_date>
</DOC>